Epitinib

Drug Profile

Epitinib

Alternative Names: Epitinib succinate; HMPL-813; Huposuan yipitini

Latest Information Update: 06 Dec 2016

Price : $50

At a glance

  • Originator Hutchison MediPharma
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Epidermal growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Non-small cell lung cancer
  • Phase I Solid tumours
  • Preclinical Oesophageal cancer

Most Recent Events

  • 29 Nov 2016 Preliminary efficacy and safety data from a phase Ib trial in Solid tumours released by Hutchison MediPharma
  • 17 Aug 2016 Phase-I/II clinical trials in Non-small cell lung cancer (First-line therapy, Metastatic disease) in China (PO) (Hutchison MediPharma pipeline, August 2016)
  • 02 Aug 2016 Hutchison MediPharma plans a phase II trial for Glioblastoma in China
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top